Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
前收盤價
US$3.15
+US$0.01 · +0.32%
盤中時間採用ET。市場資料可能有所延遲。
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
日內區間
目前US$3.15
52週區間
目前US$3.15
盤中時間採用ET。市場資料可能有所延遲。
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
日內區間
目前US$3.15
52週區間
目前US$3.15
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 122.14億 USD | 144.01億 USD | 149.48億 USD | 135.17億 USD | 124.26億 USD |
| 銷貨成本 | 115.1億 USD | 135.72億 USD | 140.99億 USD | 126.77億 USD | 118.05億 USD |
| 毛利 | 7.04億 USD | 8.29億 USD | 8.49億 USD | 8.4億 USD | 6.21億 USD |
| 銷售、一般及管理費用 | 6.55億 USD | 3.85億 USD | 6.73億 USD | 6.64億 USD | 7.2億 USD |
| 營業費用 | 7.14億 USD | 8.27億 USD | 11.99億 USD | 12.11億 USD | 12.63億 USD |
| 利息收入 | 377.92萬 USD | 704.1萬 USD | 883.4萬 USD | 811.8萬 USD | 977.6萬 USD |
| 利息支出 | 3460.28萬 USD | 2833.1萬 USD | 2014.1萬 USD | 1344.3萬 USD | 548.8萬 USD |
| 折舊和攤銷 | 1184萬 USD | 1696.7萬 USD | 2178萬 USD | 4081.9萬 USD | 2722.1萬 USD |
| 營業利益 | −1002.81萬 USD | 211.4萬 USD | −3.5億 USD | −3.71億 USD | −6.42億 USD |
| 淨利 | −1684.33萬 USD | −6474.3萬 USD | −3.93億 USD | −4.17億 USD | −6.7億 USD |
公司資料更新於 2026年10月12日。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。